Open access
Open access
Powered by Google Translator Translator

Randomized trial: Adjuvant capecitabine in triple-negative breast cancer

13 Jan, 2021 | 01:40h | UTC

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial – JAMA

Commentaries: Capecitabine maintenance may improve TNBC outcomes – medwire News

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.